Clinical trial
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
NCT00025129 · Vion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00025129 |
|---|---|
| Title | VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas |
| Official title | A Phase I Trial of VNP4010M, A Novel Alkylating Agent for Patients With Advanced or Metastatic Cancer |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | laromustine |
| Start date | Mar 1, 2001 |
| Completion | May 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: